Scholarlink

Background <p>Primary pediatric non-hepatoblastoma (n-HB) liver tumors are rare with limited literature on their clinical-epidemiological profile and outcomes. We audit the above in this study.</p> Methods <p>Children diagnosed with n-HB primary liver tumors from January 2012 to December 2023 were analyzed retrospectively. Patients underwent contrast-enhanced computed tomography (CECT) of the abdomen and computed tomography (CT) of the thorax or fluorodeoxyglucosepositron emission tomography/computed tomography (FDG-PET/CT)&#xa0;for staging of malignant tumors. Treatment was administered based on the definitive diagnosis.</p> Results <p>Sixty-nine patients formed the study cohort. The most common tumors in various age groups were infantile hepatic hemangioma (IHH)—66.7%, malignant rhabdoid tumor (MRT)—25%; six&#xa0;months to three&#xa0;years: MRT—25.0%, mesenchymal hamartoma and hemangioendothelioma—18.7% each; three to 10&#xa0;years: hepatocellular carcinoma (HCC)—31.6%, undifferentiated embryonal sarcoma of the liver (UESL)—26.3%; and &gt; = 10&#xa0;years: HCC—45.4%, UESL—22.7%. Median alpha-fetoprotein (AFP) level in HCC was 131,249&#xa0;ng/mL. Treatment was delivered to 65.8% patients. Chemotherapy for treated malignant tumors was administered in 81.5%, surgery in 85.2% and radiotherapy in 18.5%, alone or combined. In the different malignant cancer sub-types, the proportion of relapse/deaths in treated patients was HCC—22.2%, UESL—33.3%, rhabdoid—25%, hemangioendotheliomas—25% and sarcomas—25%.</p> Conclusions <p>There was a high proportion of malignant rhabdoid tumors and higher serum AFP levels in HCC in our cohort. The overall outcomes of treated malignant tumors were relatively favorable, though limited by the sample size in this rare cohort.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Primary non-hepatoblastoma liver tumors in children—Defining the profile of a very rare subset of childhood tumors

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月18日

查看全文
  • Abha Mehta,
  • Badira Cheriyalinkal Parambil,
  • Akshay Baheti,
  • Venkata Ram Mohan Gollamudi,
  • Maya Prasad,
  • Vasundhara Patil,
  • Sajid Qureshi,
  • Mukta Ramadwar,
  • Poonam Panjwani,
  • Kunal Gala,
  • Siddhartha Laskar,
  • Nehal Khanna,
  • Jifmi Jose Manjali,
  • Sneha Shah,
  • Girish Chinnaswammy

摘要

Background

Primary pediatric non-hepatoblastoma (n-HB) liver tumors are rare with limited literature on their clinical-epidemiological profile and outcomes. We audit the above in this study.

Methods

Children diagnosed with n-HB primary liver tumors from January 2012 to December 2023 were analyzed retrospectively. Patients underwent contrast-enhanced computed tomography (CECT) of the abdomen and computed tomography (CT) of the thorax or fluorodeoxyglucosepositron emission tomography/computed tomography (FDG-PET/CT) for staging of malignant tumors. Treatment was administered based on the definitive diagnosis.

Results

Sixty-nine patients formed the study cohort. The most common tumors in various age groups were infantile hepatic hemangioma (IHH)—66.7%, malignant rhabdoid tumor (MRT)—25%; six months to three years: MRT—25.0%, mesenchymal hamartoma and hemangioendothelioma—18.7% each; three to 10 years: hepatocellular carcinoma (HCC)—31.6%, undifferentiated embryonal sarcoma of the liver (UESL)—26.3%; and > = 10 years: HCC—45.4%, UESL—22.7%. Median alpha-fetoprotein (AFP) level in HCC was 131,249 ng/mL. Treatment was delivered to 65.8% patients. Chemotherapy for treated malignant tumors was administered in 81.5%, surgery in 85.2% and radiotherapy in 18.5%, alone or combined. In the different malignant cancer sub-types, the proportion of relapse/deaths in treated patients was HCC—22.2%, UESL—33.3%, rhabdoid—25%, hemangioendotheliomas—25% and sarcomas—25%.

Conclusions

There was a high proportion of malignant rhabdoid tumors and higher serum AFP levels in HCC in our cohort. The overall outcomes of treated malignant tumors were relatively favorable, though limited by the sample size in this rare cohort.

Graphical Abstract